Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes

Diabetes Care

Volumn 20, Issue 8, 1997, Pages 1304-1309

  Nagi, Dinesh K ^a,d   McCormack, Lynn J ^b   Mohamed Ali, Vidya ^c   Yudkin, John S ^c   Knowler, William C ^a   Grant, Peter J ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; DIABETIC RETINOPATHY; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION;

EID: 0030741923     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.8.1304     Document Type: Article

References (42)

1. Wiman B, Hamsten A: The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 26:207-216, 1990
2. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8:68-72, 1988
3. Juhan Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P: Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic subjects: relationship with plasma insulin. Thromb Haemost 61:370-373, 1989
4. Hamstén A, Walldius G, Szamosi A, de-Faire U, Dahlen G, Landou C, Wiman B, Blomback M: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii:3-8, 1987
5. Gray R, Yudkin JS, Patterson D: Plasminogen activator inhibitor: a risk factor for acute myocardial infarction in diabetic patients. Br Heart J 69:228-232, 1993
6. Nagi DK, Mohamed Ali V, Jain SK, Walji S, Yudkin JS: Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance or non-diabetic Asians. Diabet Med 12:59-64, 1996
7. Gough SCL, Rice PJS, McCormack L, Chapman C, Grant PJ: The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med 10:638-642, 1993
8. Dawson S, Hamsten A, Wiman B, Henny A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11:183-190, 1991
9. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries S, Yudkin JS: Polymorphism in the promoter of the plasminogen activator (PAI-1) gene as a strong determinant of PAI-1 activity in non-insulin-dependent diabetes. Diabetes 44:37-42, 1995
10. Eriksson P, Kallin B, van T Hooft FM, Bavenholm P, Hamsten A: Allele specific increase in basal transcription of the plasminogen activator inhibitor gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855, 1995
11. Knowler WC, Bennett PH, Hamman RF, Miller M: Diabetes incidence and prevalence in Pima Indians: a 19 fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 108:497-505, 1978
12. Knowler WC, Bennett PH, Bottazzo GF, Doniach D: Islet cell antibodies and diabetes mellitus in Pima Indians. Diabetologia 17:161-164, 1979
13. Dorf A, Ballintine EJ, Bennett PH, Miller M: Retinopathy in Pima Indians, relationship to glucose level, duration of diabetes, age at diagnosis of diabetes and age at examination in a population with a high prevalence of diabetes mellitus. Diabetes 25:554-560, 1976
14. Knowler WC, Bennett PH, Ballintine EJ: Increased incidence of retinopathy in diabetics with elevated blood pressure: a six-year follow-up study in Pima Indians. N Engl J Med 302:645-650, 1980
15. Nelson RG, Wolfe JA, Horton MB, Pettitt DJ, Bennett PH, Knowler WC: Proliferative retinopathy in NIDDM: incidence and risk factors in Pima Indians. Diabetes 38:435-440, 1989
16. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
17. Merimee TJ: Diabetic retinopathy: a synthesis of perspectives. N Engl J Med 322: 978-983, 1990
18. Haitas B, Barnes AJ, Cederholm-Williams SA, Moore J, Shogry MEC, Turner RC: Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microangiopathy. Diabetologia 27:483-496, 1984
19. Ostermann H, Tschope D, Greber W, Meyer-Rusenberg HW, van de Loo J: Enhancement of spontaneous fibrinolytic activity in diabetic retinopathy. Thromb Haemost 68:400-403, 1992
20. Nilsson TK, Lithner F: Glycaemic control, smoking habits and diabetes duration affect extrinsic fibrionolytic system in type 1 diabetic patients but microangiopathy does not. Acta Med Scand 224:123-129, 1988
21. Walmsley D, Hampton KK, Grant PJ: Contrasting fibrinolytic responses in type 1 (insulin dependent) and type 2 (non-insulin dependent) diabetes. Diabet Med 8:954-959, 1990
22. Vicari AM, Vigano D'Angelo S, Testa S, Comi G, Galardi G, Orsi E, D'Angelo A: Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus. Horm Metab Res 24:516-519, 1992
23. Rydzewski A, Kawamura H, Watanbe I, Takada Y, Takada A: Plasminogen activator inhibitor (PAI-1) in type II diabetes mellitus. Fibrinolysis 4:183-188, 1990
24. Garcia Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia A: Hypofibrinolysis associated with vasculopathy in non-insulin dependent diabetes mellitus. Thromb Res 59:51-59, 1990
25. Mansfield MW, Grant PJ: Fibrinolysis with diabetic retinopathy in NIDDM. Diabetes Care 18:1577-1581, 1995
26. Mansfield MW, Stickland MH, Carter AM, Grant PJ: Polymorphism of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 71:731-736, 1994
27. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985, p. 9-17 (Tech. Rep. Ser., no. 727)
28. 27a. Chasson AL, Grady HJ, Stanley MA: Determination of creatinine by means of automatic chemical analysis. Am J Clin Pathol 35:83-88, 1966
29. Chmielewska J, Ranby M, Wiman B: Evidence of a rapid inhibitor to tissue plasminogen activators in plasma. Thromb Res 31:427-436, 1983
30. Mansfield MW, Stickland MH, Grant PJ: Environmental and genetic factors in relation to circulating levels of plasminogen activator inhibtor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74:842-847, 1995
31. Falk G, Svensson H, Almqvist A, Wiman B: Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene (Abstract). Fibrinolysis 8 (Suppl.):45, 1994
32. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89:6998-7002, 1992
33. Juhan-Vague I, Alessi MC: Plasminogen activator inhibitor-1 and atherothrombosis. Thrombo Haemost 70:138-143, 1993
34. Kario K, Matsuo T, Kobayashi H, Matuso M, Sakata T, Miyata T: Activation of tissue-induced coagulation and endothelial dysfunction in non-insulin dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 15:1114-1120, 1995
35. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ: Plasminogen activator (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arterioscl Thromb Cell Biol 17:33-37, 1997
36. McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ: Promoter (4G/5G) PAI-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of insulin resistance syndrome. Diabetologia 39:1512-1518, 1996
37. Munjal ID, McLean NV, Grant MB, Blake DA: Differences in the synthesis and secreted proteins in human retinal endothelial cells of diabetic and non-diabetic origin. Curr Eye Res 13:303-310, 1994
38. Grant MB, Guay C: Plasminogen activator production by human retinal endothelial cells of non-diabetic and diabetic origin. Invest Ophthalmol Vis Sci 32:53-64, 1991
39. Maiello M, Boeri D, Podesta F, Cagliero E, Vichi M, Odetti P, Adezeti L, Lorenzi M: Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 41:1009-1015, 1992
40. Schneider DJ, Nordt TK, Sobel BE: Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 41:890-895, 1992
41. Roy S, Cagliero E, Lorenzi M: Fironectin overexpression in retinal microvessels in patients with diabetes. Invest Ophthalmol Vis Sci 37:258-266, 1996
42. Cagliero E, Roth T, Roy S, Maiello M, Lorenzi M: Expression of genes related to extracellular matrix in human endothelial cells: differential modulation by elevated glucose concentrations, phorbol esters, and cAMP. J Biol Chem 266:14244-14250, 1991